Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 3/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546390 | 0.90 | FOLH1 (0.49) | FOLH1ADRA1ASIRT5KDM4EMAPK1 | |
| SCHEMBL25546472 | 0.90 | SIRT6 (0.49) | FOLH1SIRT5ALBSIRT6SIRT1 | |
| SCHEMBL25543988 | 0.82 | ADRA1A (0.43) | FOLH1ADRA1AKDM4EMAPK1HIF1A | |
| SCHEMBL18513227 | 0.82 | NMT1 (0.54) | NMT2NMT1NOD1GLP1R | |
| SCHEMBL25546409 | 0.81 | SIRT6 (0.42) | FOLH1SIRT5SIRT6SIRT1NMT2 | |
| SCHEMBL22227375 | 0.79 | NMT2 (0.52) | SIRT6SIRT1NMT2NMT1NOD1 | |
| SCHEMBL19156036 | 0.79 | NMT2 (0.52) | SIRT6SIRT1NMT2NMT1NOD1 | |
| SCHEMBL25546377 | 0.79 | SIRT6 (0.54) | FOLH1SIRT5KDM4EMAPK1HIF1A | |
| SCHEMBL24119974 | 0.78 | NOD1 (0.45) | SIRT6SIRT1NOD1GLP1R | |
| SCHEMBL24235520 | 0.78 | NOD1 (0.40) | FOLH1ALBSIRT6SIRT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | FOLH1 677/4885ADRA1A 4275/4885SIRT5 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.